Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07579468

Impact of Physical Activity During Pregnancy on Biological Markers at Birth in Cord Blood (CORDOMOUV)

Currently, an interventional protocol for physical activity during pregnancy is underway at the Clermont University Hospital (PREGMOUV study). In addition, we have implemented a protocol for 2 years monitoring of children birthed of this study (NEOMOUV study).

Recent data from the scientific literature show that a woman's engagement in regular and appropriate physical activity during her pregnancy presents few dangers while ensuring benefits for the mother-baby dyad. Indeed, physical activity reduces maternal complications such as preeclampsia, gestational diabetes and depression and has many advantages for the child with in particular a reduction in the risk of macrosomia then obesity and diabetes.

Neonatal sepsis is a major risk factor for childhood mortality. There is strong negative association between cord blood levels of calprotectin and sepsis risk in human newborns with levels of calprotectin at birth are significantly lower in infants that later experience blood-culture-proven late-onset neonatal sepsis. In adults, plasma calprotectin levels increase following acute exercise. However after 4 weeks trainging plasma calprotectin level decrease. So in response to acute exercise, plasma calprotectin levels increase but in contrast, there is a negative association between basal plasma calprotectin levels and regular physical activity. Therefore, we do not know what impact mother' regular physical activity can have on the level of calprotectin in the cord blood.

The objective of this project is to investigate the impact of physical activity during pregnancy on calprotectin value at cord blood.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

1 day–2 day

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, 63000, France

Location status: Recruiting

Location contact

Lise Laclautre

CONTACT

[email protected]

+334754963

Solène Fel

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newborns born to mothers who participated in the PregMouv study (which aims to evaluate an intervention allowing women to better adhere to physical activity: program free/face-to-face/videoconference/mixed) and born at the Clermont Ferrand University Hospital.

Exclusion criteria

  • If parents refuse to participate or in situations where parents are protected by law, cord blood collection cannot be done.

Treatment and study plan

physical activity level during pregnancy

Behavioral

Total physical activity time (in MET minutes/week) of pregnant women measured at Trimestry 3 (explanatory variable)

Primary outcomes

  1. Calprotectin levels

    Time frame: at birth

    Calprotectin levels (ng/mL), collected from cord blood immediately after birth according to Total physical activity time (in MET minutes/week) of pregnant women measured at Trimestry 3

Secondary outcomes

  1. calprotectin level

    Time frame: at birth

    Calprotectin levels (ng/mL) in umbilical cord blood at birth according to delivery mode

  2. calprotectin level

    Time frame: at birth

    Calprotectin levels (ng/mL) in umbilical cord blood at birth according to maternal physical activity levels during pregnancy at T2

  3. calprotectin level

    Time frame: at birth

    Calprotectin levels (ng/mL) in umbilical cord blood at birth according to gestational age at birth

  4. calprotectin level

    Time frame: at birth

    Calprotectin levels (ng/mL) in umbilical cord blood at birth according to sedentary lifestyle levels at T2 and T3

  5. calprotectin level

    Time frame: at birth

    Calprotectin levels (ng/mL) in umbilical cord blood at birth according to maternal body composition (kg/m²)

  6. transcriptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to maternal body composition (kg/m²)

  7. transciptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to delivery mode

  8. transciptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to maternal physical activity levels during pregnancy at T2

  9. transciptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to gestational age at birth

  10. transciptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to sedentary lifestyle levels at T2 and T3

  11. transciptomic

    Time frame: at birth

    mRNA expression level in umbilical cord blood at birth according to maternal body composition (kg/m²)

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Laclautre

CONTACT

[email protected]

+334752963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: CORDOMOUV

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 12, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.